Marie-Louise Fjällskog, MD, Ph.D

Education/Background:  Marie-Louise is an MD (specialist in oncology), having received her degree in medicine from Uppsala University, where she also defended her thesis in 2002 and became an Associate Professor of Oncology in 2008. Marie-Louise has more than 25 years of experience in clinical oncology, translational research, and drug development. She is currently the Chief Medical Officer at Faron Pharmaceuticals. Her prior experience includes CMO at Sensei Biotherapeutics in Boston, USA, Global Clinical Program Leader at Novartis Institute for Biomedical Research (NIBR), where she worked with Translational Clinical Oncology (TCO) and had global responsibility for the development of targeted therapies for CDK4/6, BCL-2, and immunotherapy (CSF-1, PD-1, and CD73). She was Vice President (VP) of Clinical Development at Merus and Infinity Pharmaceuticals, Cambridge, USA.

Current Assignments:  Chief Medical Officer at Faron Pharmaceuticals. Board member at Lytix Biopharma AS.

Stock options: 20,000 TO10